[« back]
Press Release 01.07.2008
mtm laboratories appoints Bob Silverman as CEO
Heidelberg, Germany; July 1st, 2008. mtm laboratories, a privately held biotech company globally developing, manufacturing and commercializing in vitro diagnostics for cervical cancer screening, today announced that it has appointed Bob Silverman as its new CEO. Mr Silverman has been the mtm's Chief Commercial Officer and the President of the mtm US subsidiary since mid 2005.
Dr Gerald Möller, Chairman of mtm laboratories' supervisory board commented:
"Bob joined us at a pivotal point when mtm was preparing to bring its first products to the market and has played a key role in the successful commercialization of CINtec® Histology, CINtec® Cytology and the Cervatec™ Assay. His contributions have been crucial to the evolution of mtm into an integrated, global operation. We are confident that he possesses the skills and the leadership qualities to take mtm to the next stage in the development and commercialization of mtm?s products."
Bob Silverman, new Chief Executive Officer of mtm laboratories, commented on his appointment: "I am honored to be stepping into the role of CEO at mtm laboratories. And, I am appreciative of the role that Dr. Pack has played in bringing mtm and its technologies from groundbreaking discovery right up to commercialization."
Dr. Peter Pack, who hands over as CEO to Bob Silverman, added:
"Over the past few years, mtm laboratories has emerged as a fully integrated diagnostics company. Bob brings a strong commercial dimension and international leadership to the Company, and I wish him and mtm every success."
Heidelberg will continue to be the Company's headquarters though Mr Silverman is based at the US subsidiary in Westborough, Massachusetts.
The basis of mtm's IVD products, the proprietary p16INK4a biomarker, is strongly over-expressed in pre-cancerous and cancerous cells of the cervix. Screening and diagnostic tools based on this biomarker are developed to improve the accuracy and efficiency for the screening and early diagnosis of cervical cancer. mtm's CINtec® in vitro diagnostic products focus on the detection of p16INK4a over-expression in biopsies (CINtec® Histology) and cervical cytology specimens (CINtec® Cytology). Recently, the Company launched the biochemical based product Cervatec™ Assay, using ELISA technology for the detection of p16INK4a over-expression.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.
Press Release 01.07.2008
mtm laboratories appoints Bob Silverman as CEO
Heidelberg, Germany; July 1st, 2008. mtm laboratories, a privately held biotech company globally developing, manufacturing and commercializing in vitro diagnostics for cervical cancer screening, today announced that it has appointed Bob Silverman as its new CEO. Mr Silverman has been the mtm's Chief Commercial Officer and the President of the mtm US subsidiary since mid 2005.
Dr Gerald Möller, Chairman of mtm laboratories' supervisory board commented:
"Bob joined us at a pivotal point when mtm was preparing to bring its first products to the market and has played a key role in the successful commercialization of CINtec® Histology, CINtec® Cytology and the Cervatec™ Assay. His contributions have been crucial to the evolution of mtm into an integrated, global operation. We are confident that he possesses the skills and the leadership qualities to take mtm to the next stage in the development and commercialization of mtm?s products."
Bob Silverman, new Chief Executive Officer of mtm laboratories, commented on his appointment: "I am honored to be stepping into the role of CEO at mtm laboratories. And, I am appreciative of the role that Dr. Pack has played in bringing mtm and its technologies from groundbreaking discovery right up to commercialization."
Dr. Peter Pack, who hands over as CEO to Bob Silverman, added:
"Over the past few years, mtm laboratories has emerged as a fully integrated diagnostics company. Bob brings a strong commercial dimension and international leadership to the Company, and I wish him and mtm every success."
Heidelberg will continue to be the Company's headquarters though Mr Silverman is based at the US subsidiary in Westborough, Massachusetts.
The basis of mtm's IVD products, the proprietary p16INK4a biomarker, is strongly over-expressed in pre-cancerous and cancerous cells of the cervix. Screening and diagnostic tools based on this biomarker are developed to improve the accuracy and efficiency for the screening and early diagnosis of cervical cancer. mtm's CINtec® in vitro diagnostic products focus on the detection of p16INK4a over-expression in biopsies (CINtec® Histology) and cervical cytology specimens (CINtec® Cytology). Recently, the Company launched the biochemical based product Cervatec™ Assay, using ELISA technology for the detection of p16INK4a over-expression.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with headquarters in Heidelberg, Germany and subsidiaries in the United States, France, Italy and Spain. Further information can be found at: www.mtmlabs.com.
® mtm laboratories AG, all rights reserved